These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33558202)

  • 1. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.
    Kumar A; Bantilan KS; Jacob AP; Park A; Schoninger SF; Sauter C; Ulaner GA; Casulo C; Faham M; Kong KA; Grewal RK; Gerecitano J; Hamilton A; Hamlin P; Matasar M; Moskowitz CH; Noy A; Palomba ML; Portlock CS; Younes A; Willis T; Zelenetz AD
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):230-237.e12. PubMed ID: 33558202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
    Wu S; Blombery P; Westerman D; Tam CS
    Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
    Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
    Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
    Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
    Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
    Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
    Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Merryman RW; Redd RA; Taranto E; Ahmed G; Jeter E; McHugh KM; Brown JR; Crombie JL; Davids MS; Fisher DC; Freedman AS; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Jacene H; Park H; Dahi PB; Nieto Y; Joyce RM; Chen YB; Shipp MA; Herrera AF; Armand P
    Blood Adv; 2023 Sep; 7(17):4748-4759. PubMed ID: 36399518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
    Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
    Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
    Hoster E; Pott C
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
    Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
    Liu H; Johnson JL; Koval G; Malnassy G; Sher D; Damon LE; Hsi ED; Bucci DM; Linker CA; Cheson BD; Stock W
    Haematologica; 2012 Apr; 97(4):579-85. PubMed ID: 22102709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance.
    Ladetto M; Tavarozzi R; Pott C
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):887-901. PubMed ID: 32861285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
    Ferrero S; Grimaldi D; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Ferrante M; Evangelista A; Mantoan B; De Luca G; Stefani PM; Benedetti F; Casaroli I; Zanni M; Castellino C; Pavone V; Petrini M; Re F; Hohaus S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M
    Blood; 2022 Sep; 140(12):1378-1389. PubMed ID: 35737911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Genuardi E; Romano G; Beccuti M; Alessandria B; Mannina D; Califano C; Rota Scalabrini D; Cortelazzo S; Ladetto M; Ferrero S; Calogero RA; Cordero F
    Br J Haematol; 2021 Jul; 194(2):378-381. PubMed ID: 34002365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
    Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.